EMEA-002203-PIP01-17
Key facts
| Active substance |
Capmatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0305/2017
|
| PIP number |
EMEA-002203-PIP01-17
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of lung malignant neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Ltd
Tel. +41 61 3241111
E-mail: pediatrics.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|